Lung CancerNCT07122245
Demographics of Lung Cancer in Females
An observational study of Lung Cancer, run by Mansoura University Hospital at 1 site in Egypt.
Trial summary
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Demographics and risk factors of lung cancer
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 7 Aug 2025to 7 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Who may be able to join
- All female patients presented with bronchogenic carcinoma patients and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Who cannot join
- lung metastasis ( not primary bronchogenic carcinoma)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mohamed Mansour contact
Egypt1 site, 1 recruiting
- Recruiting
Mohamed AbdElmoniem
Al Mansurah, 35516
Mohamed AbdElmoniem, 01014008473, dr.m1993@mans.edu.eg
About this study
Official title: Demographics of Lung Cancer in Female Patients: A Retrospective Based Analysis
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others.
Read the detailed description
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others.
Moreover, a large proportion of people living in low and middle income countries are exposed to secondhand smoke (SHS) in their homes, workplaces, and other public places.
Although, lung cancer had become one of fatality causes of the 20th century due to an increasing life span combined with exposures to various etiologic factors, it is one of the leading causes of preventable deaths.
There are various important risk factors other than tobacco smoking that can contribute substantially to the lung cancer mortality in never smokers; these other lung carcinogens often act in an additive or synergistic manner in individuals who smoke tobacco products.
- Conditions
- Lung Cancer
- Being tested
- Demographics and risk factors of lung cancer
- Keywords
- Demographics, lung cancer, female patients
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Demographics and risk factors of lung cancerBehavioural
A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU).
| Study group | Role | What they receive |
|---|---|---|
| bronchogenic carcinoma in female patients | A retrospective cohort study will be conducted on bronchogenic carcinoma female patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU). Receives: Behavioral: Demographics and risk factors of lung cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Risk factors of lung cancer in females
A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2025
- Study start7 Aug 2025
- Primary completion7 Dec 2026 (estimated)
- Study completion7 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mansoura University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abd Elmoniem Mohamed, Mansoura University Hospital
- Investigators
- Mohamed AbdElmoniem, Principal investigator, Lecturer of chest medicine faculty of medicine Mansoura university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07122245
- Sponsor's protocol ID
- R.25.07.3275
- Status last verified
- Aug 2026
- First submitted
- 7 Aug 2025
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Demographics of Lung Cancer in Female Patients: A Retrospective Based Analysis
- ClinicalTrials.gov ID
- NCT07122245
- Acronym / sponsor ID
- R.25.07.3275
- Conditions
- Lung Cancer
- Keywords
- Demographics, lung cancer, female patients
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Mansoura University HospitalUniversity, hospital or other
- Study start
- 7 Aug 2025 (actual)
- Primary completion
- 7 Dec 2026 (estimated)
- Study completion
- 7 Apr 2027 (estimated)
- First posted
- 14 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others.
Detailed description
Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others.
Moreover, a large proportion of people living in low and middle income countries are exposed to secondhand smoke (SHS) in their homes, workplaces, and other public places.
Although, lung cancer had become one of fatality causes of the 20th century due to an increasing life span combined with exposures to various etiologic factors, it is one of the leading causes of preventable deaths.
There are various important risk factors other than tobacco smoking that can contribute substantially to the lung cancer mortality in never smokers; these other lung carcinogens often act in an additive or synergistic manner in individuals who smoke tobacco products.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| bronchogenic carcinoma in female patients | – | Behavioral: Demographics and risk factors of lung cancerA retrospective cohort study will be conducted on bronchogenic carcinoma female patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU). |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Key inclusion criteria (1 listed)
- All female patients presented with bronchogenic carcinoma patients and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Key exclusion criteria (1 listed)
- lung metastasis ( not primary bronchogenic carcinoma)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Demographics and risk factors of lung cancerA retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU). | Behavioural | bronchogenic carcinoma in female patients |
Primary outcome
Risk factors of lung cancer in females
Time frame: 6 months
A retrospective cohort study will be conducted on bronchogenic carcinoma patients who had been presented to and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed Mansour contact
Mohamed AbdElmoniem principal investigator
Lecturer of chest medicine faculty of medicine Mansoura university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by Mansoura University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed AbdElmoniem (01014008473, dr.m1993@mans.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Risk factors of lung cancer in females (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.